# Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction

Study · id `cardio:ct-nct04970238` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04970238](<https://clinicaltrials.gov/study/NCT04970238>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04970238

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

## Technical summary

Registry record NCT04970238. Randomized; double masking; primary purpose prevention. Start 2021-10 (anticipated); primary completion 2023-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT04970238, source copy `cardio:ctgov-nct04970238-2021-08-20`, retrieved 2026-10-26)
- Planned start: 2021-10 (anticipated) (ClinicalTrials.gov record NCT04970238, source copy `cardio:ctgov-nct04970238-2021-08-20`, retrieved 2026-10-26)
- Primary completion: 2023-01 (anticipated) (ClinicalTrials.gov record NCT04970238, source copy `cardio:ctgov-nct04970238-2021-08-20`, retrieved 2026-10-26)
- Completion: 2023-01 (anticipated) (ClinicalTrials.gov record NCT04970238, source copy `cardio:ctgov-nct04970238-2021-08-20`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04970238, source copy `cardio:ctgov-nct04970238-2021-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04970238-2021-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction
- Condition: ST Elevation Myocardial Infarction
- Condition: Heart Failure
- Intervention (Drug): Levosimendan
- Intervention (Other): placebo
- Lead sponsor: Zhijun Sun
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Zhijun Sun (`cardio:org-zhijun-sun`)

## Provenance

Content hash: 7c8812b4a1cba96edb69e12cbee1db29f01127e8332e16ed40d71bf71956d481
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
